Skip to main content

ADVERTISEMENT

enzalutamide

Conference Coverage
02/15/2021
Journal of Clinical Pathways
Conference Coverage
02/15/2021
Journal of Clinical Pathways
Research in Review
01/05/2017
JCP Editors
Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...
Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...
...
01/05/2017
Journal of Clinical Pathways